LUND, Sweden, Sept. 5, 2012 /PRNewswire/ -- BONESUPPORT, an emerging leader in injectable bone substitutes for orthopedic trauma, bone infections and instrument augmentation related to orthopedic surgery, today announced the signing of a multi-year exclusive distribution agreement with Biomet, Inc., a global leader in the manufacture of musculoskeletal medical products. Under the agreement, Biomet will have exclusive distribution rights for BONESUPPORT's proprietary CERAMENT™|BONE VOID FILLER product line in the United States and Canada for Orthopedics, Trauma and Foot and Ankle indications.
The agreement is an important step in BONESUPPORT's planned commercialization strategy to expand access and accelerate adoption of the CERAMENT product portfolio.
"The completion of this agreement with such a distinguished partner as Biomet is an endorsement of the CERAMENT product line," said Lloyd Diamond, CEO of BONESUPPORT. "In Biomet we have found an experienced partner dedicated to bringing innovative treatments to the world."
Mr. Diamond added, "Biomet's leadership position and strong distribution channel provide full and immediate territory coverage for CERAMENT in two critical markets, the United States and Canada and provides an excellent platform from which we can launch future product line extensions."
"We are very excited to be partnering with BONESUPPORT to bring the CERAMENT product line to the U.S. and Canadian markets," said Joel Higgins, Vice President and General Manager of Biomet Biologics. "Not only does CERAMENT complement our existing portfolio of products, this agreement demonstrates our commitment to bring innovative products to market which offer better therapeutic options to our customers and improved care for their patients."
For more information about BONESUPPORT and CERAMENT, visit www.BONESUPPORT.com.
BONESUPPORT is an emerging leader of injectable bone substitutes for orthopedic trauma focusing on bone infection, instrument augmentation related to orthopedic surgery and spinal applications. CERAMENT™ is a fully developed product platform that is commercially available in the U.S. and Europe and is revolutionizing the treatment of fragility and other fractures caused by disease and trauma. Scientific research of CERAMENT spans more than eleven years and over forty-five pre-clinical, clinical and animal studies have been conducted. More than 4,000 patients have been treated with CERAMENT. The company was founded in 1999 and is based in Lund, Sweden with subsidiary locations in the US and Germany. To learn more about BONESUPPORT please visit www.bonesupport.com.
Biomet, Inc. and its subsidiaries design, manufacture and market products used primarily by musculoskeletal medical specialists in both surgical and non-surgical therapy. Biomet's product portfolio encompasses large joint reconstructive products, including orthopedic joint replacement devices, and bone cements and accessories; sports medicine, extremities and trauma products, including internal and external orthopedic fixation devices; spine and bone healing products, including spine hardware, spinal stimulation devices, and orthobiologics, as well as electrical bone growth stimulators and soft goods and bracing; dental reconstructive products; and other products, including microfixation products and autologous therapies. Headquartered in Warsaw, Indiana, Biomet and its subsidiaries currently distribute products in approximately 90 countries.
Chief Financial Officer
Phone: +46 46 286 5360